Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.

BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.

Polycythemia Vera (PV)

Essential Thrombocythemia (ET)

Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.

Ruxolitinib

BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).

Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie

Universitätsklinikum Ulm Klinik für Innere Medizin III

Rems-Murr Klinikum Winnenden

Studienzentrum Aschaffenburg

III. Medizinischen Klinik des Klinikums rechts der Isar der TU München

Klinikum Nürnberg Nord Medizinische Klinik 5

Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik

Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III

Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik

Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie

Universitätsklinikum Essen Klinik für Hämatologie

Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin

Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie

Marienhospital

Zentrum für ambulante Hämatologie und Onkologie (ZAHO)

Uniklinik RWTH Aachen

InVO - Institut für Versorgungsforschung in der Onkologie

Universitätsklinikum Magdeburg

Universitätsklinikum Halle (Saale)

Klinikum Chemnitz gGmbH Klinik für Innere Medizin III

Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I

Charité Universitätsmedizin Berlin Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie

Universitätsklinikum Freiburg - Klinik für Innere Medizin I

Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie

Universitätsklinik Jena - Klinik für Innere Medizin II

Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik I

UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009

RWTH Aachen University

Novartis Pharmaceuticals

We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.
We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan.

These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.
They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.
They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction.

Blood samples will be taken, and the serum frozen and stored for further analysis pending ethical approval.

Myocardial Infarction

Fibrosis

Neovascularization, Pathologic

Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Cardiac MRI scan

Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

CT-PET scan

CT-coronary angiogram following CT-PET scan. Standard protocol.

CT-coronary angiogram

University of Edinburgh

Angiogenesis and Fibrosis in Myocardial Infarction

The Identification of In Vivo Angiogenesis and Fibrosis in Myocardial Infarction Using Positron Emission Tomography.

Imatinib 200 mg p.o. once a day for 6 months

Systemic Sclerosis

Imatinib

Università Politecnica delle Marche

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study

Paolo Fraticelli/MD

Azienda Ospedaliera Universitaria Policlinico

Glioblastoma Multiforme

Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.

Sunitinib

Homepage of the Medical University Innsbruck

LKH Feldkirch

Medical University Innsbruck

LNK Wagner-Jauregg

Paracelsus Medical University

Medical University Vienna

Kaiser-Franz-Josef Spital Wien

University Hospital of Heidelberg

University Hospital of Mannheim

University Hospital of Bonn

University Hospital of Berlin

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies

Pfizer

hyperplasia

tyrosine

hyperplasia/tyrosine

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Angiogenesis and Fibrosis in Myocardial Infarction

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı